(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
18 September 2014 (18.09.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/144632 A3

(51) **International Patent Classification**:
C07K 16/28 (2006.01) *A61P 25/06* (2006.01)
A61K 39/395 (2006.01)

(21) **International Application Number**:
PCT/US2014/029128

(22) **International Filing Date**:
14 March 2014 (14.03.2014)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/792,678 15 March 2013 (15.03.2013) US

(71) **Applicant**: **AMGEN INC.** [US/US]; One Amgen Center Drive, M/S 28-2-C, Thousand Oaks, California 91320-1799 (US).

(72) **Inventors**: **XU, Cen**; 5221 Via Jacinto, Newbury Park, California 91320 (US). **HAMBURGER, Agnes Eva**; 3885 Calle Alta Vista, Newbury Park, California 91320 (US).

(74) **Agent**: **SHOLTZ, Charles K.**; Amgen Inc., 1120 Veterans Blvd., ASF-2, South San Francisco, California 94080 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,

[Continued on next page]

(54) **Title**: HUMAN PAC1 ANTIBODIES

Seq Group	Sequence	SEQ ID NO:
CDRH1-1	R F A M H	223
CDRH1-3	R Y A M H	225
CDRH1-4	R Y G V S	226
CDRH1-9	S Y G I S	231
CDRH1-10	S Y Y W S	232
CDRH1-11	Y Y A I H	233
CDRH1-C1	R Y A M H S F G V S Y Y I W	257

Seq Group	Sequence	SEQ ID NO:
CDRH1-2	R G G Y Y W S	224
CDRH1-5	S G G F Y W S	227
CDRH1-6	S G G Y Y W S	228
CDRH1-7	S N S A A W N	229
CDRH1-8	S N S A T W N	230
CDRH1-C2	R G G Y Y W S S N S F A N A T	258

Seq Group	Sequence	SEQ ID NO:
CDRH2-3	Y I Y Y – S – G N T Y Y N P S L K S	241
CDRH2-1	R I Y T – S – G S T N Y N P S L K S	234
CDRH2-2	R T Y Y R S K W S N H Y A V S V K S	235
CDRH2-3	R T Y Y R S R W Y N D Y A V S V K S	236
CDRH2-C1	R T Y Y R S K W S N H Y A V S V K S Y I T – R G N T N N P L – Y Y D	259

Seq Group	Sequence	SEQ ID NO:
CDRH2-4	V I S Y D G G N K Y Y A E S V K G	237
CDRH2-5	V I S Y D G S N K Y Y A D S V K G	238
CDRH2-C2	V I S Y D G G N K Y Y A E S V K G S D	260

Seq Group	Sequence	SEQ ID NO:
CDRH2-6	W I N A Y N G H T N Y A Q T F Q G	239
CDRH2-7	W I T T Y N G N T N Y A Q K L Q G	240
CDRH2-C3	W I N A Y N G H T N Y A Q T F Q G T T N K L	261

Seq Group	Sequence	SEQ ID NO:
CDRH3-3	G T W K Q L W F L D H	236
CDRH3-4	G V F Y S K G A F D I	245
CDRH3-5	G Y D I L T G Y P D Y	246
CDRH3-6	G Y D V L T G Y P D Y	247
CDRH3-9	G Y D L L T G Y P D Y	250
CDRH3-C1	G Y D V L T G Y P D Y T W K Q L W F L H V F Y S K A F I L	262

Fig. 2

(57) **Abstract**: Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine and cluster headache.

WO 2014/144632 A3

TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
20 November 2014